FOLD

8.16

3.20% -0.27

Handel nachbörslich: 8.16

Amicus Therapeutics Inc (FOLD)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt FOLD? Forum Prognose

Schlusskurs vom Vortag:

$8.43

Offen:

$8.31

24-Stunden-Volumen:

4.34M

Relative Volume:

1.94

Marktkapitalisierung:

$2.64B

Einnahmen:

$493.67M

Nettoeinkommen (Verlust:

$-104.69M

KGV:

-24.00

EPS:

-0.34

Netto-Cashflow:

$-31.51M

1W Leistung:

-6.10%

1M Leistung:

-14.01%

6M Leistung:

-23.60%

1J Leistung:

-30.73%

1-Tages-Spanne:

$7.97

$8.31

1-Wochen-Bereich:

$7.97

$8.71

52-Wochen-Spanne:

$7.97

$12.65

Amicus Therapeutics Inc Stock (FOLD) Company Profile

Firmenname

Amicus Therapeutics Inc

Sektor

Healthcare (1164)

Branche

Biotechnology (681)

Telefon

(609) 662-2000

Adresse

47 HULFISH STREET, PRINCETON, NJ

Mitarbeiter

Twitter

@amicusrx1

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

FOLD's Discussions on Twitter

Vergleichen Sie FOLD mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
FOLD Amicus Therapeutics Inc	8.16	2.64B	493.67M	-104.69M	-31.51M	-0.34
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-13	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-09-06	Eingeleitet	Jefferies	Buy
2024-05-30	Eingeleitet	Wells Fargo	Overweight
2024-05-14	Hochstufung	Guggenheim	Neutral → Buy
2023-12-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2022-04-13	Fortgesetzt	Goldman	Neutral
2022-01-14	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2021-11-15	Hochstufung	Stifel	Hold → Buy
2021-09-30	Hochstufung	JP Morgan	Neutral → Overweight
2021-07-19	Fortgesetzt	BTIG Research	Buy
2021-05-27	Eingeleitet	Needham	Hold
2021-05-21	Eingeleitet	UBS	Buy
2021-04-14	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2021-03-02	Eingeleitet	Stifel	Hold
2021-02-12	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2021-02-12	Herabstufung	JP Morgan	Overweight → Neutral
2020-12-28	Fortgesetzt	Cantor Fitzgerald	Overweight
2020-12-10	Herabstufung	Citigroup	Buy → Neutral
2020-11-11	Eingeleitet	Berenberg	Hold
2020-06-17	Eingeleitet	BTIG Research	Buy
2020-02-04	Fortgesetzt	Cantor Fitzgerald	Overweight
2019-11-12	Bestätigt	H.C. Wainwright	Buy
2019-06-17	Eingeleitet	H.C. Wainwright	Buy
2019-06-05	Bestätigt	Cantor Fitzgerald	Overweight
2019-04-05	Eingeleitet	Janney	Buy
2019-01-30	Eingeleitet	Cantor Fitzgerald	Overweight
2018-10-29	Eingeleitet	Citigroup	Neutral
2018-08-17	Herabstufung	Chardan Capital Markets	Buy → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral
2017-09-13	Bestätigt	Chardan Capital Markets	Buy
2017-08-10	Bestätigt	Chardan Capital Markets	Buy
2017-01-24	Hochstufung	Robert W. Baird	Neutral → Outperform
2016-05-18	Eingeleitet	BofA/Merrill	Buy
2016-04-14	Eingeleitet	Robert W. Baird	Neutral
2016-04-12	Bestätigt	Chardan Capital Markets	Buy
2015-09-16	Herabstufung	Chardan Capital Markets	Buy → Neutral
2015-06-16	Bestätigt	Chardan Capital Markets	Buy

Alle ansehen

Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten

03:10 AM

How To Trade (FOLD) - news.stocktradersdaily.com

03:10 AM

02:25 AM

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

02:25 AM

Mar 29, 2025

Amicus Therapeutics (NASDAQ:FOLD) Sets New 52-Week LowShould You Sell? - MarketBeat

Mar 29, 2025

Mar 28, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Fox Run Management L.L.C. - MarketBeat

Mar 28, 2025

Amicus Therapeutics (NASDAQ:FOLD) Trading Down 2.5%Time to Sell? - MarketBeat

Mar 28, 2025

Mar 27, 2025

Is Amicus Therapeutics (NASDAQ:FOLD) A Risky Investment? - simplywall.st

Mar 27, 2025

Mar 26, 2025

Intech Investment Management LLC Has $1.18 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Mar 26, 2025

Pompe Disease Treatment Market Size in 7MM is expected to grow at - openPR.com

Mar 26, 2025

Mar 25, 2025

Amicus Therapeutics stock hits 52-week low at $8.54 By Investing.com - Investing.com UK

Mar 25, 2025

Semanteon Capital Management LP Purchases 43,288 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Mar 25, 2025

Mar 24, 2025

Pompe Disease Treatment Market reached US$ 1.39 billion in 2024 - openPR.com

Mar 24, 2025

Primecap Management Co. CA Sells 94,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Mar 24, 2025

Mar 22, 2025

Victory Capital Management Inc. Reduces Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Mar 22, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Charles Schwab Investment Management Inc. - MarketBeat

Mar 22, 2025

Mar 21, 2025

Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 21, 2025

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio - Yahoo Finance

Mar 21, 2025

Connor Clark & Lunn Investment Management Ltd. Has $2.85 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Mar 21, 2025

Mar 20, 2025

Great Lakes Advisors LLC Lowers Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Mar 19, 2025

Mar 17, 2025

Is Amicus Therapeutics Inc. (FOLD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey

Mar 17, 2025

Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade) (NASDAQ:FOLD) - Seeking Alpha

Mar 17, 2025

Mar 15, 2025

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Inceptionr LLC - MarketBeat

Mar 15, 2025

Mar 13, 2025

Amicus Therapeutics (NASDAQ:FOLD) Reaches New 52-Week LowTime to Sell? - MarketBeat

Mar 13, 2025

Pompe Disease Treatment Market Size in the 7MM is expected - openPR

Mar 13, 2025

Essex Investment Management Co. LLC Has $2.18 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat

Mar 13, 2025

Mar 12, 2025